VX-509

Vertex Pharmaceuticals Incorporated · Phase 2 active Small molecule

At a glance

Generic name	VX-509
Sponsor	Vertex Pharmaceuticals Incorporated
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate (PHASE2)
A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis (PHASE2, PHASE3)
A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor (PHASE2)
Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects (PHASE1)
A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis (PHASE2)
Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VX-509 CI brief — competitive landscape report
VX-509 updates RSS · CI watch RSS
Vertex Pharmaceuticals Incorporated portfolio CI